HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings

Seaport Therapeutics, Inc. (NASDAQ:SPTX) – HC Wainwright lowered their FY2026 earnings per share estimates for Seaport Therapeutics in a research report issued on Tuesday, August 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($4.09) for the year, down from their prior estimate of ($3.25). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ Q1 2027 earnings at ($0.62) EPS, Q3 2027 earnings at ($0.67) EPS and FY2027 earnings at ($2.62) EPS.

Several other analysts have also recently commented on the company. Leerink Partners began coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 target price on the stock. Seaport Research Partners set a $50.00 price target on Seaport Therapeutics in a research report on Wednesday, July 15th. JPMorgan Chase & Co. initiated coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued an “overweight” rating and a $42.00 price target for the company. UBS Group lowered Seaport Therapeutics to a “sell” rating in a report on Tuesday, June 9th. Finally, BNP Paribas Exane downgraded shares of Seaport Therapeutics to a “market perform” rating in a report on Tuesday, May 26th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $38.40.

Seaport Therapeutics Stock Performance

Shares of NASDAQ:SPTX opened at $22.34 on Thursday. The firm has a 50-day moving average price of $19.52. The company has a market cap of $1.20 billion and a P/E ratio of -2.16. Seaport Therapeutics has a fifty-two week low of $14.85 and a fifty-two week high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($1.07).

Insider Activity

In related news, Director Robert J. Hombach acquired 13,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $235,820. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.